Johnson & Johnson gets FDA nod for new depression treatment
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups
The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Subscribe To Our Newsletter & Stay Updated